Greek clinicians say pharmaceutical innovation is reshaping patient care, with new research pointing to benefits beyond the health system
Medicines should be treated as an investment, not a cost. That is the conclusion of new European research finding that Greece’s €93mn spend on innovative therapies returned €557mn in economic and social value over eight years.
The WifOR Institute study links newer medicines to 25,600 fewer years of life lost prematurely and 252,400 fewer hospital days – clinical gains that clinicians say have transformed daily practice.
The study found that new therapies are changing the way Greek physicians treat diseases ranging from severe asthma to cancer, reducing hospitalisations and helping patients live longer, healthier lives, while generating significant economic benefits.
For doctors treating patients every day, pharmaceutical innovation is no longer an abstract discussion about research pipelines or drug approvals. It has fundamentally changed clinical practice.
